Genetic Testing in Pheochromocytoma or Functional Paraganglioma
Inserm · Université Paris Cité · +1 more institution
Abstract
We have identified 86 patients (27.4%) with a hereditary tumor. Among the 56 patients with a family/syndromic presentation, 13 have had neurofibromatosis type 1, and germline mutations on the VHL, RET, SDHD, and SDHB genes were present in 16, 15, nine, and three patients, respectively. Among the 258 patients with an apparently sporadic presentation, 30 (11.6%) had a germline mutation (18 patients on SDHB, nine patients on VHL, two patients on SDHD, and one patient on RET). Mutation carriers were younger and more frequently had bilateral or extra-adrenal tumors. In patients with an SDHB mutation, the tumors were larger, more frequently extra-adrenal, and malignant.
Genetic testing oriented by family/sporadic presentation should be proposed to all patients with pheo or functional pgl. We suggest an algorithm that would allow the confirmation of suspected inherited disease as well as the diagnosis of unexpected inherited disease.
Citation impact
- FWCI
- 27.62
- Percentile
- 100%
- References
- 17
Authors
20- LALaurence AmarCorresponding
Inserm, Université Paris Cité, Institut Cochin
- JBJérôme Bertherat
Inserm, Université Paris Cité, Institut Cochin
- ÉBÉric Baudin
Inserm, Université Paris Cité, Institut Cochin
- CAChristiane Ajzenberg
Inserm, Université Paris Cité, Institut Cochin
- BBBrigitte Bressac–de Paillerets
Inserm, Université Paris Cité, Institut Cochin
Topics & keywords
- SDHB
- SDHD
- Medicine
- Paraganglioma
- Pheochromocytoma
- Neurofibromatosis
- Germline mutation
- Proband
- Good health and well-being